

General Assembly

Substitute Bill No. 6571

January Session, 2005

*HB06571HS	_APP032405
------------	------------

AN ACT CONCERNING THE AVAILABILITY OF MAINTENANCE DRUGS UNDER THE CONNPACE PROGRAM.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- Section 1. Section 17b-491 of the general statutes is repealed and the following is substituted in lieu thereof (*Effective July 1, 2005*):
- 3 (a) There shall be a "Connecticut Pharmaceutical Assistance
 4 Contract to the Elderly and the Disabled Program" which shall be
 5 within the Department of Social Services. The program shall consist of
 6 payments by the state to pharmacies for the reasonable cost of
 7 prescription drugs dispensed to eligible persons minus a copayment
 8 charge. The pharmacy shall collect the copayment charge from the
 9 eligible person at the time of each purchase of prescription drugs, and
 10 shall not waive, discount or rebate in whole or in part such amount.
- 11 Except for a replacement prescription dispensed pursuant to section
- 12 17b-492, the copayment for each prescription shall be as follows:
- 13 (1) Sixteen dollars and twenty-five cents if the participant is (A) not 14 married and has an annual income of less than twenty thousand three 15 hundred dollars, or (B) married and has an annual income that, when 16 combined with the participant's spouse, is less than twenty-seven
- 17 thousand five hundred dollars.
- 18 (2) Upon the granting of a federal waiver to expand the program in

- 19 accordance with section 17b-492, the copayment shall be twenty
- 20 dollars for a participant who is (A) not married and has an annual
- 21 income that equals or exceeds twenty thousand three hundred dollars,
- 22 or (B) married and has an annual income that, when combined with
- 23 the participant's spouse, equals or exceeds twenty-seven thousand five
- 24 hundred dollars.
- 25 (b) On January 1, 2002, and annually thereafter, the commissioner 26 shall increase the income limits established in subsection (a) of this 27 section that set the appropriate participant copayment by the increase 28 in the annual inflation adjustment in Social Security income, if any.
- 29 Each such adjustment shall be determined to the nearest one hundred
- 30 dollars.

38

39

40

41

42

43

44

45

46

47

48

49

50

- 31 (c) Notwithstanding the provisions of subsection (a) of this section, 32 effective September 15, 1991, payment by the state to a pharmacy 33 under the program may be based on the price paid directly by a pharmacy to a pharmaceutical manufacturer for drugs dispensed 34 35 under the program minus the copayment charge, plus the dispensing 36 fee, if the direct price paid by the pharmacy is lower than the 37 reasonable cost of such drugs.
 - (d) Effective September 15, 1991, reimbursement to a pharmacy for prescription drugs dispensed under the program shall be based upon actual package size costs of drugs purchased by the pharmacy in units larger than or smaller than one hundred.
 - (e) The commissioner shall establish an application form whereby a pharmaceutical manufacturer may apply to participate in the program. Upon receipt of a completed application, the department shall issue a certificate of participation to the manufacturer. Participation by a pharmaceutical manufacturer shall require that the department shall receive a rebate from the pharmaceutical manufacturer. Rebate amounts for brand name prescription drugs shall be equal to those under the Medicaid program. Rebate amounts for generic prescription drugs shall be established by the commissioner, provided such

amounts may not be less than those under the Medicaid program. A participating pharmaceutical manufacturer shall make quarterly rebate payments to the department for the total number of dosage units of each form and strength of a prescription drug which the department reports as reimbursed to providers of prescription drugs, provided such payments shall not be due until thirty days following the manufacturer's receipt of utilization data from the department including the number of dosage units reimbursed to providers of prescription drugs during the quarter for which payment is due.

- (f) All prescription drugs of a pharmaceutical manufacturer that participates in the program pursuant to subsection (e) of this section shall be subject to prospective drug utilization review. Any prescription drug of a manufacturer that does not participate in the program shall not be reimbursable [,] unless the department determines the prescription drug is essential to program participants.
- 66 (g) On and after July 1, 2005, the commissioner shall allow any eligible person to obtain a maintenance drug in a ninety-day supply if 67 (1) the ninety-day supply is authorized by a licensed practitioner, and 68 69 (2) the individual has obtained an initial supply of the maintenance 70 drug under the program. Nothing in this section shall prohibit an eligible person from obtaining a maintenance drug in any other 71 72 amount permitted under the program. As used in this section, 73 "maintenance drug" means a prescription drug designated as a 74 maintenance drug by the commissioner but does not include a 75 schedule II controlled substance.
- 76 Sec. 2. Section 17b-494 of the general statutes is repealed and the 77 following is substituted in lieu thereof (*Effective July 1, 2005*):
 - The Commissioner of Social Services shall adopt regulations, in accordance with the provisions of chapter 54, to establish (1) a system for determining eligibility and disqualification under the program, including provisions for an identification number and a renewable, nontransferable identification card; (2) requirements for the use of the

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

78

79

80

81

82

83 identification number and card by the pharmacy and the eligible 84 person; (3) a system of payments; (4) limitations on the maximum 85 quantity per prescription which shall not exceed (A) with respect to 86 any refill of a maintenance drug, a ninety-day supply or one hundred 87 twenty oral dosage units, whichever is greater, or (B) with respect to 88 any prescription that is not subject to subparagraph (A) of this 89 <u>subdivision</u> a thirty-day supply or one hundred twenty oral dosage 90 units whichever is greater; (5) requirements as to records to be kept by 91 the pharmacy, including patient profiles; (6) products prescribed for 92 cosmetic and other purposes which shall not be covered under the 93 program; and (7) such other provisions as are necessary to implement 94 the provisions of sections 17b-490 to 17b-495, inclusive.

95 Sec. 3. Section 17b-362 of the general statutes is repealed. (Effective 96 July 1, 2005)

This act shall take effect as follows and shall amend the following		
sections:		
Section 1	July 1, 2005	17b-491
Sec. 2	July 1, 2005	17b-494
Sec. 3	July 1, 2005	17b-362 repealed

AGE Joint Favorable Subst. C/R HS HS Joint Favorable C/R **APP**